PUBLIC COMPANY
saveAAVantgarde Bio Srl
founded 2021 · Milan, ITupdated 1mo ago
AAVantgarde Bio is an Italian clinical-stage biotechnology company developing AAV-based gene therapies for inherited retinal diseases. It operates two proprietary large-gene delivery platforms (dual hybrid and AAV intein) and is a TIGEM spin-out co-founded by Professor Alberto Auricchio. Lead programs target Stargardt disease and Usher syndrome type 1B.
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
comments(0)
5-min edit window · permanent after that